



## Company Overview

Heat Biologics is a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

## Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

Sep 9 2020, 7:30 AM EDT

## Heat Biologics Issued Key Patent on Combination Platform Therapy

Sep 2 2020, 7:30 AM EDT

## Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results

Aug 26 2020, 7:30 AM EDT

## Stock Overview

Symbol	HTBX
Exchange	Nasdaq
Market Cap	220.56m
Last Price	\$1.405
52-Week	\$0.195 - \$4.30

09/18/2020 04:00 PM EDT

## Investor Relations

[investorrelations@heatbio.com](mailto:investorrelations@heatbio.com)

## Management Team

### Jeffrey Wolf

Founder, Chairman and CEO

### Jeff Hutchins, Ph.D.

Chief Scientific and Operating Officer

### George Peoples, M.D., FACS

Chief Medical Advisor

### Lori McDermott, RN, BSN, MS, PMP

Vice President, Clinical Development

### William L. Ostrander

Vice President of Finance and Secretary

### Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

### Cheni Kwok, Ph.D., CLP

Senior Business Development Advisor

### Matthew M. Seavey, Ph.D.

Executive Director of Research

---

## Heat Biologics, Inc.

627 Davis Drive  
Suite 400  
Morrisville, NC 27560

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.